Gerresheimer AG

Gerresheimer AG

GRRMF
Gerresheimer AGUS flagOther OTC
32.10
USD
- -
- -
1.11BMarket Cap
2012 Y
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
TTM
Revenue per Share
38.82
40.32
41.08
40.86
43.8
42.94
43.56
44.34
45.18
47.71
57.87
59.71
58.94
63.35
Basic EPS, GAAP
1.98
1.98
2.11
3.32
3.87
3.21
4.11
2.57
2.82
2.67
3.06
3.48
3.18
1.83
Free Cash Flow per Basic Share
1.74
0.88
1.04
2.48
2
3.27
1.88
6.14
1.56
0.27
7.07
8.83
6.96
6.93
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1.25
Book Value per Share
-0.35
0.79
1.96
4.6
7.61
9.88
13.57
14.61
16.09
18.16
20.57
21.47
22.6
22.67
Tangible Book Value per Share
0.27
-0.29
1.49
-17.62
-13.71
-9.93
-19.6
-13.24
-11.93
-8.73
-1.53
6.28
8.63
-7.97
Basic Weighted Avg Shares
31
31
31
31
31
31
31
31
31
31
31
33
35
35
Sales/Revenue/Turnover
1,219
1,266
1,290
1,283
1,375
1,348
1,368
1,392
1,419
1,498
1,817
1,990
2,036
2,188
Operating Margin (%)
11.45
11.07
11.32
10.33
13.33
13.38
14.05
2.39
12.75
12.64
10.66
11.53
11.47
9.68
Depreciation Expense
84
83
104
109
126
125
137
270
146
145
172
186
199
237
Net Income, GAAP
62
62
66
104
122
101
129
81
89
84
96
116
110
63
Effective Tax Rate (%)
30.65
30.65
26.67
29.41
28.89
29.17
- -
15.78
33.49
31.77
27.43
28.28
23.5
23.32
Profit Margin (%)
5.09
4.91
5.14
8.12
8.84
7.48
9.43
5.8
6.24
5.59
5.29
5.83
5.39
2.89
Working Capital
120
53
46
-130
2
42
-196
-346
-27
-229
-291
-108
7
8
LT Debt
408
389
371
727
730
681
674
497
837
695
685
658
916
1,702
Total Equity
538
563
604
698
763
790
890
942
900
1,015
1,269
1,472
1,539
1,466
Return on Invested Capital (%)
9.46
9.43
9.77
6.57
7.61
7.29
- -
1.46
6.1
6.27
6.01
6.49
6.62
5.16
Return on Capital (%)
16.32
15.79
14.48
13.36
8.4
9.79
- -
6.87
6.59
5.74
6.1
8.07
7.92
5.58
Return on Common Equity (%)
- -
- -
153.56
101.15
63.46
36.75
35.03
18.26
18.37
15.58
15.81
17.06
14.66
8.37

Capital Structure

FRC

in mil. unless spec.
Aug'24
Nov'24
May'25
ST Debt
605
366
505
LT Borrowings
- -
871
- -
LT Finance Leases
- -
45
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
35
35
35
Market Capitalization
3,415
2,893
2,258

Working Capital

FRC

in mil. unless spec.
Aug'24
Nov'24
May'25
Total Current Assets
877
992
1,138
Cash, Cash Equivalents & STI
131
213
203
Accounts Receivable, Net
273
311
291
Inventories
372
350
505
Total Current Liabilities
1,089
986
1,130
Payables & Accruals
- -
- -
- -
ST Debt
605
366
505
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
10.08%
10.79%
4.54%
Free Cash Flow
275.13%
476.69%
-18.35%
Net Income, GAAP
8.15%
6.85%
-5.52%
Sales/Revenue/Turnover
4.85%
8.12%
2.28%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
458
500
488
545
1,990
2024
466
502
499
569
2,036
2025
520
601
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
0.38
1.05
0.81
- -
3.48
2024
0.38
0.94
0.79
- -
3.18
2025
-0.52
0.49
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
1.25
- -
- -
2024
- -
- -
1.25
- -
- -
2025
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Uwe Ferdinand Röehrhoff
Full Time Employees
13,632
Sector
Healthcare
Industry
Medical - Instruments & Supplies
Address
Klaus-Bungert-Strasse 4 Düsseldorf Germany 40468
IPO Date
Sep 11, 2009
Business
Gerresheimer AG is a global provider specializing in the manufacture and supply of pharmaceutical and healthcare packaging products. The company offers a broad portfolio including primary packaging made of glass and plastic; injection molding; glass tubular products; prefillable syringes; inhalers; insulin pens; bottles and ampoules; and other drug delivery systems. Gerresheimer serves pharmaceutical and biotech companies, medical device manufacturers, and cosmetic industries, operating across Europe, the Americas, and Asia. Founded in 1864 and headquartered in Düsseldorf, Germany, Gerresheimer AG focuses on integrated solutions for the pharmaceutical and healthcare sectors, emphasizing innovation and quality compliance. Its business is segmented into industries such as pharma packaging, drug delivery devices, and consumer packaging. The company also maintains subsidiaries and production sites worldwide to support its extensive client base. In recent major developments within the last 1-2 years, Gerresheimer AG has expanded its strategic alliances in the pharmaceutical delivery systems market, launched new high-tech product offerings such as advanced inhalers and prefillable syringes, and pursued business expansions to enhance manufacturing capabilities and geographic reach. The company has also undertaken operational improvements to optimize supply chain and production efficiency to meet rising global demand. These moves aim to strengthen its competitive position as a premier provider of pharmaceutical packaging solutions. Overall, Gerresheimer AG is a leading manufacturer of specialized pharmaceutical glass and plastic packaging and injection-molded products, delivering innovative drug delivery systems and packaging solutions primarily for pharmaceutical, biotech, and medical device industries on a global scale, with ongoing strategic initiatives driving growth and product development.

Company News

APIChat
  • Gerresheimer rejects takeover bid from US packing firm Silgan, say sources

  • Gerresheimer delays 2025 results release to June, stock to be removed from SDAX

  • Diamond Hill International Strategy Q4 2025 Portfolio Review

  • Gerresheimer appoints Uwe Röhrhoff as new interim CEO

  • Gerresheimer finds 2024 revenue-recognition issues after external probe

  • Gerresheimer AG (GRRMY) Q3 2025 Earnings Call Transcript

  • Gerresheimer's shares fall 11% after another outlook cut

  • Gerresheimer cuts 2025 outlook again as Q3 disappoints

  • Gerresheimer shares tank as financial regulator suspects accounting flaws

  • Activist investor wants review at Gerresheimer after taking stake

  • Gerresheimer shares rise on plan to sell moulded glass business

  • Gerresheimer calls a halt to discussions on potential takeover

  • Gerresheimer cuts its 2025 revenue outlook for second time

  • AVI Calls for Changes at Gerresheimer

  • UK fund Asset Value Investor calls for changes at Gerresheimer

  • Gerresheimer cuts guidance for 2025 citing weak demand

  • Gerresheimer: Strong Growth Projections Make Stock Look Cheap

  • Gerresheimer AG (GRRMF) Q1 2025 Earnings Call Transcript

  • Gerresheimer's first-quarter results hit by low demand in moulded glass

  • KKR drops out of consortium seeking Gerresheimer takeover, Bloomberg News reports